



OLIGOMERIX, Inc.

Press Release

FOR IMMEDIATE RELEASE

Victor P. Micati Joins OLIGOMERIX's Board of Directors

New York, NY – August 8, 2007 (BUSINESS WIRE) - OLIGOMERIX Inc. today announced that Victor P. Micati has been appointed to the Company's Board of Directors. A global pharmaceutical executive, Mr. Micati worked at Pfizer Inc. (NYSE: PFE) for nearly 40 years. He was a member of Pfizer's 10-member Corporate Management Committee responsible for all aspects of global operations. He also served as Executive Vice President of the Pharmaceutical group and Vice President of Pfizer Inc, and was responsible for Pfizer's European pharmaceutical operations and Global Consumer Health Care group. He was appointed to the International Board of Directors in 1984 and became President of Pfizer's European operations in 1990.

Since his retirement in 1999, Mr. Micati has worked as a consultant in the pharmaceutical industry and served on the Board of several companies. He was a Director at Ilex Oncology (Nasdaq: ILXO) subsequently acquired by Genzyme Corporation (Nasdaq: GENZ), and a member of the Advisory Board of Almirall, a Spanish pharmaceutical company. Since 2004 he has been a member of the Board at ENZON Pharmaceuticals Inc. (Nasdaq: ENZN).

"We are extremely fortunate to have Victor Micati join, he brings a wealth of experience and expertise to the Board" said David Dantzker, MD, Chairman. "We are anticipating that Vic will play a pivotal role in guiding and establishing important collaborations within the pharmaceutical industry, and that his strong leadership skills and global knowledge of the industry will be a tremendous asset as we transition into a leading biopharmaceutical company," said James Moe, President & CEO.

ABOUT OLIGOMERIX

OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located within the Audubon Biomedical Science and Technology Park of Columbia University. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases.

For more information visit www.oligomerix.com.

Certain matters described in this news release may be forward-looking statements subject to risks and uncertainties that could cause actual results to differ materially from those indicated. Such risks and uncertainties include, but are not limited to, the risk of dependence on market growth, competition, dependence on government agencies and other third parties for funding and services.

CONTACT: OLIGOMERIX, Inc.
James Moe, President and CEO
212-568-0365 Ext. 18

SOURCE: OLIGOMERIX, Inc.